EA201892797A1 - Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака - Google Patents

Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака

Info

Publication number
EA201892797A1
EA201892797A1 EA201892797A EA201892797A EA201892797A1 EA 201892797 A1 EA201892797 A1 EA 201892797A1 EA 201892797 A EA201892797 A EA 201892797A EA 201892797 A EA201892797 A EA 201892797A EA 201892797 A1 EA201892797 A1 EA 201892797A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nanoparticles
segment
oligonucleotide
double
methods
Prior art date
Application number
EA201892797A
Other languages
English (en)
Russian (ru)
Inventor
Лали К. Медина-Кауве
Original Assignee
Седарс-Синаи Медикал Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Седарс-Синаи Медикал Сентер filed Critical Седарс-Синаи Медикал Сентер
Publication of EA201892797A1 publication Critical patent/EA201892797A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EA201892797A 2016-05-27 2017-05-26 Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака EA201892797A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342829P 2016-05-27 2016-05-27
PCT/US2017/034719 WO2017205764A1 (en) 2016-05-27 2017-05-26 Drug-delivery nanoparticles and treatments for drug-resistant cancer

Publications (1)

Publication Number Publication Date
EA201892797A1 true EA201892797A1 (ru) 2019-06-28

Family

ID=60411649

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892797A EA201892797A1 (ru) 2016-05-27 2017-05-26 Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака

Country Status (13)

Country Link
US (2) US20190175747A1 (https=)
EP (1) EP3463468A4 (https=)
JP (1) JP2019517477A (https=)
KR (1) KR20190013929A (https=)
CN (1) CN109475636A (https=)
AU (1) AU2017271662A1 (https=)
BR (1) BR112018074304A2 (https=)
CA (1) CA3025348A1 (https=)
EA (1) EA201892797A1 (https=)
IL (1) IL263227A (https=)
MX (1) MX2018014576A (https=)
SG (1) SG11201810403VA (https=)
WO (1) WO2017205764A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US10036009B2 (en) * 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
JP6608370B2 (ja) 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
EP3518939A4 (en) * 2016-10-03 2020-06-24 EOS Biosciences, Inc. FUNCTIONAL RNA AND THERAPEUTIC COMPLEXES WITH SMALL MOLECULAR ACTIVE SUBSTANCES AND NANOPARTICLE RELEASE VEHICLES
CA3087325A1 (en) * 2018-01-02 2019-07-11 Cedars-Sinai Medical Center Nanoparticles for the targeted delivery of therapeutic polypeptides
JP7698252B2 (ja) * 2019-09-06 2025-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療薬の核酸媒介性送達
CN115282283B (zh) * 2022-06-21 2024-11-29 上海交通大学 一种小分子药物-寡核苷酸偶联物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) * 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
EP2473160A4 (en) * 2009-09-01 2015-06-03 Univ Northwestern ADMINISTRATION OF THERAPEUTIC AGENTS WITH OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS SUPPORT
US9850293B2 (en) * 2014-04-04 2017-12-26 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
US10111898B2 (en) * 2014-08-27 2018-10-30 Peptimed, Inc. Anti-tumor compositions and methods

Also Published As

Publication number Publication date
SG11201810403VA (en) 2018-12-28
EP3463468A1 (en) 2019-04-10
CA3025348A1 (en) 2017-11-30
US20190175747A1 (en) 2019-06-13
CN109475636A (zh) 2019-03-15
EP3463468A4 (en) 2020-11-11
KR20190013929A (ko) 2019-02-11
BR112018074304A2 (pt) 2019-10-01
JP2019517477A (ja) 2019-06-24
WO2017205764A1 (en) 2017-11-30
IL263227A (en) 2018-12-31
MX2018014576A (es) 2019-06-06
US20250255978A1 (en) 2025-08-14
AU2017271662A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
EA201892797A1 (ru) Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака
MX2017007321A (es) Terapias de combinacion.
MY188825A (en) High-concentration monoclonal antibody formulations
MY166014A (en) Combination therapy methods for treating proliferative diseases
SG10201907684PA (en) Androgen receptor modulator and uses thereof
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
ZA201907225B (en) Treatment of her2 positive cancers
WO2015154059A3 (en) Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
WO2021141319A3 (ko) 뇌암세포 표적용 펩타이드로 표면 개질된 약물 전달용 나노입자, 이의 제조방법 및 이의 용도
BR112014016723A2 (pt) método para o tratamento de câncer de mama
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
NZ801252A (en) Pharmaceutical composition comprising insoluble camptothecin compound-containing nanoparticle for treatment of cancer and combination therapy thereof
WO2019126302A3 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
WO2019220441A8 (en) Compositions and methods for treating cancer resistant to an anti-cancer agent
RU2014141615A (ru) Новое противоопухолевое средство, включающее комбинацию трех агентов
WO2022241331A3 (en) Polymer-lipid hybrid nanoparticles of emricasan and use thereof
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
EA202190294A1 (ru) Комбинированная терапия для лечения рака
GR1008614B (el) 3,3-διαφαινυλ-ν-(φαινυλαιθυλ)προπαν-1-αμινη: ως νεος και επιλεκτικος προσδετης των σιγμα-1 υποδοχεων, με αντι-απο πτωτικες (κυτταρο-προστατευτικες) ιδιοτητες και με πρωτοτυπη αντικαρκινικη δραση
WO2019108685A8 (en) Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
MX393290B (es) Composicion para el tratamiento de la osteoartritis